Mucor Mycosis in COVID-19: Case Reports
Abstract
Coronavirus infections are associated with a wide range of bacterial and fungal co-infections. Use of steroids, monoclonal antibodies and broad spectrum antibiotics along with underlying pathogenesis may alter body homeostasis and exacerbate preexisting fungal disease. We report the cases with COVID-19 infection, which, after the course of the treatment, presented with various forms of mucormycosis infection.
How to cite this article:
Deshmukh R, Upadhyay K, Patwadkar R. Patil S. Mucor Mycosis in COVID-19: Case Reports. J Adv Res Med 2020; 7(3): 20-23.
DOI: https://doi.org/10.24321/2349.7181.202016
References
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases
of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020.
Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. Invasive fungal diseases during COVID-19: We
should be prepared. Journal de Mycologie Medicale 2020.
Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al. Bacterial and Fungal
Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.
Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020.4. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19.
Am J Emerg Med 2020.
Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus 2020.
Kudo K, Hasegawa H, Sato E, Kaneko T, Ishida D, Kanno C et al. A case of rhinocerebral mucormycosis extending into the skull. J Oral Maxillofac Surgery, Med Pathol 2017.